\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ revealed\\ a\\ non\\-tender\\ thyroid\\ gland\\ with\\ a\\ non\\-tender\\ palpable\\ right\\ thyroid\\ nodules\\.\\ \ \(0\)\
\-\ preoperative\\:\ \(0\)\
\-\ tsh\\ \\=\\ 160\\ mgiu\\/ml\ \(0\)\
\-\ ft4\\ \\=\\ 14\\.3\\ ng\\/dl\ \(0\)\
\-\ raiu\\:\\ 13\\.8\\%\ \(0\)\
\-\ post\\-thyroidectomy\\:\ \(0\)\
\-\ tsh\\ \\=\\ 77\\.25mg\\/ml\ \(0\)\
\-\ ft4\\ \\=\\ 0\\.06ng\\/ml\ \(0\)\
\-\ raiu\\ \\=\\ 2\\.7\\%\ \(0\)\
\-\ thyroid\\ biopsy\\ revealed\\ follicular\\ thyroid\\ cancer\\.\\ \\ the\\ patient\\ underwent\\ thyroidectomy\\.\\ \\ post\\ surgical\\ thyroid\\ scintigraphy\\ revealed\\ residual\\ thyroid\\ avid\\ tissue\\ in\\ the\\ thyroid\\ bed\\ and\\ ablation\\ with\\ high\\ dose\\ i\\ \\(131\\)\\ was\\ administered\\.\ \(0\)\
\-\ preoperative\\ thyroid\\ nuclear\\ scan\\ was\\ performed\\:\\ \\ \ \(0\)\
\-\ i\\ \\(131\\)\\ 7\\.7\\ microcurie\\ was\\ administered\\ 24\\ hours\\ prior\\ to\\ imaging\\ and\\ measurement\\ of\\ the\\ radioactive\\ uptake\\ was\\ 13\\.8\\%\\ \\(normal\\ 8\\%\\ \\-\\ 30\\%\\)\\.\\ on\\ the\\ day\\ of\\ imaging\\ technetium\\ 99m\\-pertechnetate\\ 11\\.0\\ millicurie\\ was\\ administered\\ thyroid\\ imaging\\ revealed\\ a\\ photopenic\\ region\\ in\\ the\\ lateral\\ aspect\\ of\\ the\\ right\\ thyroid\\ gland\\.\\ \\ the\\ findings\\ consistent\\ with\\ a\\ cold\\ thyroid\\ nodule\\.\\ \ \(0\)\
\-\ post\\-thyroidectomy\\ 1\\(123\\)\\ scan\\ demonstrated\\ residual\\ thyroid\\ activity\\ in\\ the\\ thyroid\\ bed\\ with\\ no\\ evidence\\ of\\ extrathyroidal\\ malignancy\\.\\ \\ i\\ \\(131\\)\\ ablation\\ therapy\\ followed\\ with\\ a\\ 185\\ millicurie\\ dose\\.\ \(0\)\
\-\ solitary\\ thyroid\\ nodule\ \(0\)\
\-\ cold\\ thyroid\\ nodule\\ differential\\ diagnosis\ \(0\)\
\-\ malignancy\ \(256\)\
\-\ hematoma\ \(500\)\
\-\ colloid\\ cyst\ \(15\)\
\-\ adenoma\ \(519\)\
\-\ abscess\ \(594\)\
\-\ parathyroid\ \(188\)\
\-\ lymphoma\ \(373\)\
\-\ lymph\\ node\ \(292\)\
\-\ thyroiditis\ \(54\)\
\-\ patient\\ presents\\ for\\ screening\\ carotid\\ ultrasound\\ and\\ a\\ 3cm\\ solitary\\ right\\ thyroid\\ nodule\\ was\\ incidentally\\ discovered\\.\\ \\ the\\ patient\\ denied\\ symptoms\\ of\\ hyperthyroidism\\ or\\ hypothyroidism\\.\ \(0\)\
\-\ pre\\-\\ total\\ thyroidectomy\\:\\ \ \(0\)\
\-\ a\\ very\\ low\\ dose\\ of\\ i\\ \\(131\\)\\,\\ which\\ has\\ a\\ suboptimal\\ imaging\\ \\ gamma\\ emission\\ of\\ 364\\ kev\\,\\ a\\ longer\\ half\\ life\\ of\\ 8\\ days\\,\\ and\\ is\\ a\\ cytotoxic\\ beta\\ minus\\ emitter\\ is\\ used\\ for\\ the\\ pre\\ surgical\\ radioactive\\ uptake\\ \\(raiu\\)\\ measurement\\.\\ thyroid\\ cancers\\ typically\\ have\\ normal\\ raiu\\.\\ \\ technetium\\-99m\\-pertechnate\\ has\\ an\\ optimal\\ imaging\\ gamma\\ emmission\\ of\\ 140\\ kev\\,\\ a\\ shorter\\ half\\ life\\ of\\ 8\\ hours\\,\\ and\\ has\\ no\\ cytotoxic\\ beta\\ emissions\\ \\.\\ \\ \\ \ \(0\)\
\-\ post\\ thyroidectomy\\ and\\ preablation\\:\\ \ \(0\)\
\-\ identifying\\ residual\\ thyroid\\ advid\\ tissue\\ within\\ the\\ thyroid\\ bed\\ and\\ beyond\\ prior\\ to\\ ablation\\.\\ \\ i123\\ has\\ an\\ optimal\\ imaging\\ gamma\\ emission\\ of\\ 159kev\\,\\ a\\ half\\ life\\ of\\ 13\\.27\\ hours\\,\\ and\\ no\\ cytotoxic\\ beta\\ emissions\\.\\ \\ \\ neck\\ and\\ pin\\-hole\\ thyroid\\ as\\ well\\ as\\ whole\\ body\\ anterior\\ and\\ posterior\\ planar\\ images\\ allow\\ identification\\ of\\ iodine\\ avid\\ tissue\\ in\\ and\\ beyond\\ the\\ thyroid\\ bed\\.\\ in\\ preparation\\ for\\ ablation\\,\\ the\\ patient\\ is\\ hypothyroid\\ secondary\\ to\\ hormone\\ replacement\\ medication\\ withdrawl\\ or\\ is\\ placed\\ on\\ thyrogen\\ \\(recombinant\\ tsh\\)\\ which\\ prevents\\ hypothyroid\\ symptoms\\.\\ \\ ablations\\ dose\\ is\\ determined\\ by\\ the\\ presence\\ of\\ absence\\ of\\ metastatic\\ disease\\ and\\ tumor\\ pathology\\.\\ \\ \\ \\ \ \(0\)\
\-\ post\\ ablation\\:\ \(0\)\
\-\ follow\\ up\\ thyroid\\ scintigraphy\\ is\\ performed\\ up\\ to\\ 10\\ days\\ but\\ not\\ earlier\\ than\\ 5\\-6\\ days\\ post\\ ablation\\ to\\ identify\\ metastatic\\ disease\\ and\\ again\\ between\\ six\\ to\\ twelve\\ month\\ to\\ identify\\ residual\\ or\\ recurrent\\ disease\\.\\ \\ \ \(0\)\
\-\ the\\ patients\\ thyroglobulin\\ levels\\ are\\ monitored\\ and\\ they\\ are\\ placed\\ on\\ hormone\\ replacement\\ therapy\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ thyroid\\:\\ 0\\.15854089256860832\ \(0\)\
\-\ ablation\\:\\ 0\\.06604669779218236\ \(0\)\
\-\ 131\\:\\ 0\\.05144501289304495\ \(0\)\
\-\ raiu\\:\\ 0\\.04832164152098813\ \(0\)\
\-\ \\=\\:\\ 0\\.04613976423539267\ \(0\)\
\-\ bed\\:\\ 0\\.04086724956589663\ \(0\)\
\-\ dose\\:\\ 0\\.03680422223961164\ \(0\)\
\-\ beta\\:\\ 0\\.03657497942018725\ \(0\)\
\-\ post\\-thyroidectomy\\:\\ 0\\.03627785359656995\ \(0\)\
\-\ millicurie\\:\\ 0\\.03627785359656995\ \(0\)\
\-\ thyroidectomy\\:\\ 0\\.03592460586674387\ \(0\)\
\-\ cytotoxic\\:\\ 0\\.035623432013846136\ \(0\)\
\-\ residual\\:\\ 0\\.034903764983235525\ \(0\)\
\-\ 13\\.8\\:\\ 0\\.033425396063401454\ \(0\)\
\-\ emissions\\:\\ 0\\.033425396063401454\ \(0\)\
\-\ gamma\\:\\ 0\\.03196254484098835\ \(0\)\
\-\ kev\\:\\ 0\\.030572938530232956\ \(0\)\
\-\ hypothyroid\\:\\ 0\\.030572938530232956\ \(0\)\
\-\ administered\\:\\ 0\\.030393198307752292\ \(0\)\
\-\ i\\:\\ 0\\.029072548931921894\ \(0\)\
\-\ nodule\\:\\ 0\\.02898941233944038\ \(0\)\
\-\ tsh\\:\\ 0\\.02864895774117815\ \(0\)\
\-\ half\\:\\ 0\\.02784847735038474\ \(0\)\
\-\ emission\\:\\ 0\\.02605190030526131\ \(0\)\
\-\ optimal\\:\\ 0\\.025417535367700576\ \(0\)\
\-\ imaging\\:\\ 0\\.02471696079574818\ \(0\)\
\-\ radioactive\\:\\ 0\\.024618539423499106\ \(0\)\
\-\ ft4\\:\\ 0\\.023949737244495915\ \(0\)\
\-\ measurement\\:\\ 0\\.023031451025095875\ \(0\)\
\-\ life\\:\\ 0\\.02301186474527231\ \(0\)\
\-\ avid\\:\\ 0\\.022870048913353976\ \(0\)\
\-\ revealed\\:\\ 0\\.022571801562683895\ \(0\)\
\-\ post\\:\\ 0\\.02214679039565674\ \(0\)\
\-\ preoperative\\:\\ 0\\.021530862080289665\ \(0\)\
\-\ cold\\:\\ 0\\.021201468221550834\ \(0\)\
\-\ identify\\:\\ 0\\.020995664021655105\ \(0\)\
\-\ hours\\:\\ 0\\.02074195869511603\ \(0\)\
\-\ \\%\\:\\ 0\\.020507418038539175\ \(0\)\
\-\ scintigraphy\\:\\ 0\\.020433624782948315\ \(0\)\
\-\ beyond\\:\\ 0\\.020433624782948315\ \(0\)\
\-\ hormone\\:\\ 0\\.01993920374656122\ \(0\)\
\-\ 8\\:\\ 0\\.019722947890428076\ \(0\)\
\-\ non\\-tender\\:\\ 0\\.018621641904601267\ \(0\)\
\-\ mgiu\\/ml\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ 77\\.25mg\\/ml\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ 0\\.06ng\\/ml\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ microcurie\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ 99m\\-pertechnetate\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ \\-adenoma\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ \\-lymph\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ \\-thyroiditis\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ emitter\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ technetium\\-99m\\-pertechnate\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ emmission\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ preablation\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ advid\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ 159kev\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ 13\\.27\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ pin\\-hole\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ thyrogen\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ recombinant\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ ablations\\:\\ 0\\.018138926798284976\ \(0\)\
\-\ solitary\\:\\ 0\\.017451882491617762\ \(0\)\
\-\ replacement\\:\\ 0\\.01716513384701698\ \(0\)\
\-\ extrathyroidal\\:\\ 0\\.016712698031700727\ \(0\)\
\-\ \\-colloid\\:\\ 0\\.016712698031700727\ \(0\)\
\-\ \\-parathyroid\\:\\ 0\\.016712698031700727\ \(0\)\
\-\ minus\\:\\ 0\\.016712698031700727\ \(0\)\
\-\ i123\\:\\ 0\\.016712698031700727\ \(0\)\
\-\ withdrawl\\:\\ 0\\.016712698031700727\ \(0\)\
\-\ \\:\\:\\ 0\\.016279678419618634\ \(0\)\
\-\ days\\:\\ 0\\.016167125285012206\ \(0\)\
\-\ 185\\:\\ 0\\.015878407685799154\ \(0\)\
\-\ gland\\:\\ 0\\.014976825890504811\ \(0\)\
\-\ \\-hematoma\\:\\ 0\\.014827326155416458\ \(0\)\
\-\ 364\\:\\ 0\\.014827326155416458\ \(0\)\
\-\ \\-abscess\\:\\ 0\\.014452178919214905\ \(0\)\
\-\ placed\\:\\ 0\\.014234288680224222\ \(0\)\
\-\ 14\\.3\\:\\ 0\\.014134996450434537\ \(0\)\
\-\ \\-malignancy\\:\\ 0\\.014134996450434537\ \(0\)\
\-\ uptake\\:\\ 0\\.013971125204502931\ \(0\)\
\-\ 123\\:\\ 0\\.013860240498532227\ \(0\)\
\-\ thyroglobulin\\:\\ 0\\.013860240498532227\ \(0\)\
\-\ 11\\.0\\:\\ 0\\.01361788857331333\ \(0\)\
\-\ 7\\.7\\:\\ 0\\.013401097388832208\ \(0\)\
\-\ has\\:\\ 0\\.013207407164561959\ \(0\)\
\-\ suboptimal\\:\\ 0\\.01320498590775335\ \(0\)\
\-\ preparation\\:\\ 0\\.01320498590775335\ \(0\)\
\-\ prevents\\:\\ 0\\.01320498590775335\ \(0\)\
\-\ twelve\\:\\ 0\\.01320498590775335\ \(0\)\
\-\ 160\\:\\ 0\\.013025950152630654\ \(0\)\
\-\ pre\\-\\:\\ 0\\.013025950152630654\ \(0\)\
\-\ technetium\\:\\ 0\\.012861253223261237\ \(0\)\
\-\ \\-lymphoma\\:\\ 0\\.012861253223261237\ \(0\)\
\-\ shorter\\:\\ 0\\.012708767683850288\ \(0\)\
\-\ 5\\-6\\:\\ 0\\.012566807042930634\ \(0\)\
\-\ tissue\\:\\ 0\\.012502599928719714\ \(0\)\
\-\ photopenic\\:\\ 0\\.012434011731947978\ \(0\)\
\-\ 140\\:\\ 0\\.012434011731947978\ \(0\)\
\-\ was\\:\\ 0\\.012200957064366504\ \(0\)\
\-\ \\(\\:\\ 0\\.011890728004014165\ \(0\)\
\-\ ng\\/dl\\:\\ 0\\.011874477337948715\ \(0\)\
\-\ \\)\\:\\ 0\\.011745476413387738\ \(0\)\
\-\ 2\\.7\\:\\ 0\\.011687292609130349\ \(0\)\
\-\ follicular\\:\\ 0\\.011599721386046405\ \(0\)\
\-\ pre\\:\\ 0\\.011599721386046405\ \(0\)\
\-\ 3cm\\:\\ 0\\.011435024456676988\ \(0\)\
\-\ planar\\:\\ 0\\.011435024456676988\ \(0\)\
\-\ hyperthyroidism\\:\\ 0\\.011357369460827509\ \(0\)\
\-\ identification\\:\\ 0\\.011073109505105663\ \(0\)\
\-\ iodine\\:\\ 0\\.011073109505105663\ \(0\)\
\-\ identifying\\:\\ 0\\.011007782965363727\ \(0\)\
\-\ allow\\:\\ 0\\.010883040945165304\ \(0\)\
\-\ cancers\\:\\ 0\\.010600734110775417\ \(0\)\
\-\ monitored\\:\\ 0\\.010600734110775417\ \(0\)\
\-\ whole\\:\\ 0\\.01035252837458485\ \(0\)\
\-\ hypothyroidism\\:\\ 0\\.010306287930444812\ \(0\)\
\-\ longer\\:\\ 0\\.00993114069424326\ \(0\)\
\-\ scan\\:\\ 0\\.009844738520300324\ \(0\)\
\-\ performed\\:\\ 0\\.009804849099700901\ \(0\)\
\-\ a\\:\\ 0\\.009792587699224722\ \(0\)\
\-\ up\\:\\ 0\\.00945616111544948\ \(0\)\
\-\ therapy\\:\\ 0\\.00940181397629882\ \(0\)\
\-\ determined\\:\\ 0\\.009174505344191166\ \(0\)\
\-\ nuclear\\:\\ 0\\.009071603244243304\ \(0\)\
\-\ prior\\:\\ 0\\.009029270667499438\ \(0\)\
\-\ medication\\:\\ 0\\.0088573228754108\ \(0\)\
\-\ metastatic\\:\\ 0\\.0088523020724942\ \(0\)\
\-\ symptoms\\:\\ 0\\.00876402253867547\ \(0\)\
\-\ earlier\\:\\ 0\\.008683947682781705\ \(0\)\
\-\ discovered\\:\\ 0\\.008663267979379437\ \(0\)\
\-\ six\\:\\ 0\\.008642794047582796\ \(0\)\
\-\ disease\\:\\ 0\\.008621836674171013\ \(0\)\
\-\ denied\\:\\ 0\\.008562876695080197\ \(0\)\
\-\ again\\:\\ 0\\.008448535437560009\ \(0\)\
\-\ node\\:\\ 0\\.00804576881795899\ \(0\)\
\-\ incidentally\\:\\ 0\\.007970938274397519\ \(0\)\
\-\ carotid\\:\\ 0\\.007884592185716383\ \(0\)\
\-\ total\\:\\ 0\\.007571440302296783\ \(0\)\
\-\ screening\\:\\ 0\\.007500070841416352\ \(0\)\
\-\ recurrent\\:\\ 0\\.007419819487911683\ \(0\)\
\-\ surgical\\:\\ 0\\.007391859136837258\ \(0\)\
\-\ absence\\:\\ 0\\.007310346162678216\ \(0\)\
\-\ nodules\\:\\ 0\\.007289133467906897\ \(0\)\
\-\ levels\\:\\ 0\\.007257718916197455\ \(0\)\
\-\ pathology\\:\\ 0\\.00719629306609523\ \(0\)\
\-\ patient\\:\\ 0\\.007050139349106074\ \(0\)\
\-\ is\\:\\ 0\\.0069418614615398225\ \(0\)\
\-\ 24\\:\\ 0\\.006836331235855864\ \(0\)\
\-\ malignancy\\:\\ 0\\.0067944232053529134\ \(0\)\
\-\ 30\\:\\ 0\\.006761500692294394\ \(0\)\
\-\ used\\:\\ 0\\.006745234890839428\ \(0\)\
\-\ activity\\:\\ 0\\.006596803762924977\ \(0\)\
\-\ which\\:\\ 0\\.006564381017459048\ \(0\)\
\-\ very\\:\\ 0\\.006382274935096974\ \(0\)\
\-\ presence\\:\\ 0\\.006382274935096974\ \(0\)\
\-\ they\\:\\ 0\\.006335280095652894\ \(0\)\
\-\ biopsy\\:\\ 0\\.006238051937524199\ \(0\)\
\-\ palpable\\:\\ 0\\.006231730540328787\ \(0\)\
\-\ typically\\:\\ 0\\.006206637385814758\ \(0\)\
\-\ or\\:\\ 0\\.006182239191133997\ \(0\)\
\-\ to\\:\\ 0\\.006151186747121201\ \(0\)\
\-\ underwent\\:\\ 0\\.00603332517588111\ \(0\)\
\-\ 10\\:\\ 0\\.00592721034639282\ \(0\)\
\-\ followed\\:\\ 0\\.005894806319709406\ \(0\)\
\-\ cancer\\:\\ 0\\.005780175441079764\ \(0\)\
\-\ body\\:\\ 0\\.005710419161911697\ \(0\)\
\-\ follow\\:\\ 0\\.005586830189190194\ \(0\)\
\-\ day\\:\\ 0\\.005582221871096563\ \(0\)\
\-\ differential\\:\\ 0\\.005582221871096563\ \(0\)\
\-\ between\\:\\ 0\\.005573036082765934\ \(0\)\
\-\ right\\:\\ 0\\.005565627834014917\ \(0\)\
\-\ aspect\\:\\ 0\\.005523234433093329\ \(0\)\
\-\ normal\\:\\ 0\\.005512808455140334\ \(0\)\
\-\ as\\:\\ 0\\.005319248995449086\ \(0\)\
\-\ no\\:\\ 0\\.005311383646319765\ \(0\)\
\-\ month\\:\\ 0\\.005274927038684382\ \(0\)\
\-\ ultrasound\\:\\ 0\\.005216301615239308\ \(0\)\
\-\ and\\:\\ 0\\.005185444609570079\ \(0\)\
\-\ neck\\:\\ 0\\.005163051722260253\ \(0\)\
\-\ demonstrated\\:\\ 0\\.005159300375425859\ \(0\)\
\-\ region\\:\\ 0\\.004966257669216693\ \(0\)\
\-\ secondary\\:\\ 0\\.004915699519565448\ \(0\)\
\-\ low\\:\\ 0\\.004889234676679835\ \(0\)\
\-\ an\\:\\ 0\\.004862818371542099\ \(0\)\
\-\ high\\:\\ 0\\.00481182317093995\ \(0\)\
\-\ are\\:\\ 0\\.004793719640039514\ \(0\)\
\-\ cyst\\:\\ 0\\.004725043489765644\ \(0\)\
\-\ evidence\\:\\ 0\\.004609964163306333\ \(0\)\
\-\ than\\:\\ 0\\.00460709640929686\ \(0\)\
\-\ patients\\:\\ 0\\.004550565019271658\ \(0\)\
\-\ anterior\\:\\ 0\\.004528380295808102\ \(0\)\
\-\ for\\:\\ 0\\.0045006675842142905\ \(0\)\
\-\ on\\:\\ 0\\.004468463039292766\ \(0\)\
\-\ \\,\\:\\ 0\\.004456132765716665\ \(0\)\
\-\ in\\:\\ 0\\.0043353624500026226\ \(0\)\
\-\ physical\\:\\ 0\\.004313796850990203\ \(0\)\
\-\ consistent\\:\\ 0\\.004311313310352271\ \(0\)\
\-\ the\\:\\ 0\\.004266953231593389\ \(0\)\
\-\ 1\\:\\ 0\\.004183799111028204\ \(0\)\
\-\ tumor\\:\\ 0\\.004099243418952287\ \(0\)\
\-\ posterior\\:\\ 0\\.004052754215437137\ \(0\)\
\-\ diagnosis\\:\\ 0\\.004037488334939136\ \(0\)\
\-\ well\\:\\ 0\\.003977532825038377\ \(0\)\
\-\ exam\\:\\ 0\\.003862621275616334\ \(0\)\
\-\ have\\:\\ 0\\.003807485757952864\ \(0\)\
\-\ lateral\\:\\ 0\\.003799728488939404\ \(0\)\
\-\ \\-\\:\\ 0\\.0037689885981653575\ \(0\)\
\-\ but\\:\\ 0\\.0037500067922500778\ \(0\)\
\-\ findings\\:\\ 0\\.0037424628308435387\ \(0\)\
\-\ of\\:\\ 0\\.0035957963209255687\ \(0\)\
\-\ presents\\:\\ 0\\.003591860690345527\ \(0\)\
\-\ images\\:\\ 0\\.0033729709710892063\ \(0\)\
\-\ within\\:\\ 0\\.003354179852646259\ \(0\)\
\-\ by\\:\\ 0\\.002927717907911265\ \(0\)\
\-\ not\\:\\ 0\\.0025407791599628303\ \(0\)\
\-\ \\.\\:\\ 0\\.001533930572107555\ \(0\)\
\-\ with\\:\\ 0\\.0012037466675914581\ \(0\)\
